A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma.

ABSTRACT:

Background

Except for B7-CD28 family members, more novel immune checkpoints are being discovered. They are closely associated with tumor immune microenvironment and regulate the function of many immune cells. Various cancer therapeutic studies targeting these novel immune checkpoints are currently in full swing. However, studies concerning novel immune checkpoints phenotypes and clinical significance in lung adenocarcinoma (LUAD) are still limited.

Methods

We enrolled 1883 LUAD cases from nine different cohorts. The samples from The Cancer Genome Atlas (TCGA) were used as a training set, whereas seven microarray data cohorts and an independent cohort with 102 qPCR data were used for validation. The immune profiles and potential mechanism of the system were also explored.

SUBMITTER: Sun N 

PROVIDER: S-EPMC9310422 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature